0 9 Clonality clonality NN 10 12 of of IN 13 21 isolated isolate VBN 22 33 eosinophils eosinophil NNS 34 36 in in IN 37 40 the the DT 41 58 hypereosinophilic hypereosinophilic JJ 59 67 syndrome syndrome NN 67 68 . . . 70 73 The the DT 74 84 idiopathic idiopathic JJ 85 102 hypereosinophilic hypereosinophilic JJ 103 111 syndrome syndrome NN 112 113 ( ( ( 113 117 IHES IHES NNP 117 118 ) ) ) 119 121 is be VBZ 122 123 a a DT 124 128 rare rare JJ 129 137 disorder disorder NN 138 151 characterized characterize VBN 152 154 by by IN 155 166 unexplained unexplained JJ 166 167 , , , 168 178 persistent persistent JJ 179 191 eosinophilia eosinophilia NN 192 202 associated associate VBN 203 207 with with IN 208 216 multiple multiple JJ 217 222 organ organ NN 223 234 dysfunction dysfunction NN 235 238 due due JJ 239 241 to to TO 242 254 eosinophilic eosinophilic JJ 255 261 tissue tissue NN 262 274 infiltration infiltration NN 274 275 . . . 276 278 In in IN 279 282 the the DT 283 290 absence absence NN 291 293 of of IN 294 304 karyotypic karyotypic JJ 305 318 abnormalities abnormality NNS 318 319 , , , 320 325 there there EX 326 328 is be VBZ 329 331 no no DT 332 340 specific specific JJ 341 345 test test NN 346 348 to to TO 349 355 detect detect VB 356 362 clonal clonal JJ 363 375 eosinophilia eosinophilia NN 376 378 in in IN 379 383 IHES ihes NN 383 384 . . . 385 393 Analysis Analysis NNP 394 396 of of IN 397 409 X-chromosome X-chromosome NNP 410 422 inactivation inactivation NN 423 431 patterns pattern NNS 432 435 can can MD 436 438 be be VB 439 443 used use VBN 444 446 to to TO 447 456 determine determine VB 457 464 whether whether IN 465 478 proliferative proliferative JJ 479 488 disorders disorder NNS 489 492 are be VBP 493 499 clonal clonal JJ 500 502 in in IN 503 509 origin origin NN 509 510 . . . 511 522 Methylation methylation NN 523 525 of of IN 526 531 HpaII HpaII NNP 532 535 and and CC 536 539 Hha Hha NNP 540 541 I i CD 542 547 sites site NNS 548 552 near near IN 553 556 the the DT 557 568 polymorphic polymorphic JJ 569 582 trinucleotide trinucleotide NN 583 589 repeat repeat NN 590 592 of of IN 593 596 the the DT 597 602 human human JJ 603 611 androgen androgen NN 612 620 receptor receptor NN 621 625 gene gene NN 626 627 ( ( ( 627 633 HUMARA HUMARA NNP 633 634 ) ) ) 635 638 has have VBZ 639 643 been be VBN 644 649 shown show VBN 650 652 to to TO 653 662 correlate correlate VB 663 667 with with IN 668 682 X-inactivation X-inactivation NNP 682 683 . . . 684 686 In in IN 687 691 this this DT 692 697 study study NN 697 698 , , , 699 701 we we PRP 702 706 have have VBP 707 711 used use VBN 712 715 the the DT 716 726 polymerase polymerase NN 727 732 chain chain NN 733 741 reaction reaction NN 742 743 ( ( ( 743 746 PCR PCR NNP 746 747 ) ) ) 748 752 with with IN 753 759 nested nested JJ 760 767 primers primer NNS 768 770 to to TO 771 778 analyze analyze VB 779 793 X-inactivation x-inactivation NN 794 802 patterns pattern NNS 803 805 of of IN 806 809 the the DT 810 816 HUMARA HUMARA NNP 817 821 loci locus NNS 822 824 in in IN 825 833 purified purify VBN 834 845 eosinophils eosinophil NNS 846 850 from from IN 851 857 female female JJ 858 866 patients patient NNS 867 871 with with IN 872 884 eosinophilia eosinophilia NN 884 885 . . . 886 896 Peripheral peripheral JJ 897 902 blood blood NN 903 914 eosinophils eosinophil NNS 915 919 were be VBD 920 928 isolated isolate VBN 929 931 by by IN 932 937 their their PRP$ 938 953 autofluoresence autofluoresence NN 954 959 using use VBG 960 964 flow flow NN 965 975 cytometric cytometric JJ 976 983 sorting sorting NN 983 984 . . . 985 996 Eosinophils eosinophil NNS 997 1005 purified purify VBN 1006 1010 from from IN 1011 1012 a a DT 1013 1019 female female JJ 1020 1027 patient patient NN 1028 1038 presenting present VBG 1039 1043 with with IN 1044 1048 IHES ihes NNS 1049 1053 were be VBD 1054 1059 found find VBN 1060 1062 to to TO 1063 1067 show show VB 1068 1069 a a DT 1070 1076 clonal clonal JJ 1077 1084 pattern pattern NN 1085 1087 of of IN 1088 1102 X-inactivation X-inactivation NNP 1102 1103 . . . 1104 1123 Eosinophil-depleted eosinophil-depleted JJ 1124 1134 leukocytes leukocyte NNS 1135 1139 from from IN 1140 1144 this this DT 1145 1152 patient patient NN 1153 1157 were be VBD 1158 1168 polyclonal polyclonal JJ 1169 1171 by by IN 1172 1178 HUMARA HUMARA NNP 1179 1187 analysis analysis NN 1187 1188 , , , 1189 1193 thus thus RB 1194 1203 excluding exclude VBG 1204 1214 skewedness skewedness NN 1215 1217 of of IN 1218 1224 random random JJ 1225 1239 X-inactivation x-inactivation NN 1239 1240 . . . 1241 1246 After after IN 1247 1261 corticosteroid corticosteroid NN 1262 1273 suppression suppression NN 1274 1276 of of IN 1277 1280 her her PRP$ 1281 1286 blood blood NN 1287 1299 eosinophilia eosinophilia NN 1299 1300 , , , 1301 1302 a a DT 1303 1309 clonal clonal JJ 1310 1320 population population NN 1321 1323 of of IN 1324 1335 eosinophils eosinophil NNS 1336 1341 could could MD 1342 1344 no no RB 1345 1351 longer longer RB 1352 1354 be be VB 1355 1363 detected detect VBN 1364 1366 in in IN 1367 1375 purified purify VBN 1376 1387 eosinophils eosinophil NNS 1387 1388 . . . 1389 1391 In in IN 1392 1400 contrast contrast NN 1400 1401 , , , 1402 1413 eosinophils eosinophil NNS 1414 1422 purified purify VBN 1423 1427 from from IN 1428 1429 a a DT 1430 1437 patient patient NN 1438 1442 with with IN 1443 1456 Churg-Strauss churg-strauss JJ 1457 1465 syndrome syndrome NN 1466 1469 and and CC 1470 1474 from from IN 1475 1478 six six CD 1479 1487 patients patient NNS 1488 1492 with with IN 1493 1501 reactive reactive JJ 1502 1515 eosinophilias eosinophilia NNS 1516 1526 attributed attribute VBN 1527 1529 to to TO 1530 1537 allergy allergy NN 1537 1538 , , , 1539 1548 parasitic parasitic JJ 1549 1558 infection infection NN 1558 1559 , , , 1560 1562 or or CC 1563 1567 drug drug NN 1568 1576 reaction reaction NN 1577 1583 showed show VBD 1584 1585 a a DT 1586 1596 polyclonal polyclonal JJ 1597 1604 pattern pattern NN 1605 1607 of of IN 1608 1622 X-inactivation X-inactivation NNP 1623 1625 by by IN 1626 1632 HUMARA HUMARA NNP 1633 1641 analysis analysis NN 1641 1642 . . . 1643 1646 The the DT 1647 1654 finding finding NN 1655 1657 of of IN 1658 1664 clonal clonal JJ 1665 1677 eosinophilia eosinophilia NN 1678 1680 in in IN 1681 1682 a a DT 1683 1690 patient patient NN 1691 1701 presenting present VBG 1702 1706 with with IN 1707 1711 IHES IHES NNP 1712 1721 indicates indicate VBZ 1722 1726 that that IN 1727 1731 such such JJ 1732 1740 patients patient NNS 1741 1744 may may MD 1745 1749 have have VB 1749 1750 , , , 1751 1753 in in IN 1754 1761 reality reality NN 1761 1762 , , , 1763 1764 a a DT 1765 1774 low-grade low-grade JJ 1775 1781 clonal clonal JJ 1782 1790 disorder disorder NN 1791 1795 that that WDT 1796 1799 can can MD 1800 1802 be be VB 1803 1816 distinguished distinguish VBN 1817 1821 from from IN 1822 1830 reactive reactive JJ 1831 1844 eosinophilias eosinophilia NNS 1845 1847 by by IN 1848 1854 HUMARA HUMARA NNP 1855 1863 analysis analysis NN 1863 1864 . . . 1865 1872 Further further RB 1872 1873 , , , 1874 1877 the the DT 1878 1884 method method NN 1885 1894 described describe VBN 1895 1898 can can MD 1899 1901 be be VB 1902 1906 used use VBN 1907 1909 to to TO 1910 1917 monitor monitor VB 1918 1925 disease disease NN 1926 1937 progression progression NN 1937 1938 . . .